TY - JOUR
T1 - Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival
AU - Griffiths, Richard W.
AU - Elkord, Eyad
AU - Gilham, David E.
AU - Ramani, Vijay
AU - Clarke, Noel
AU - Stern, Peter L.
AU - Hawkins, Robert E.
PY - 2007/11
Y1 - 2007/11
N2 - Background: Regulatory T cells are important in maintaining immune homeostasis, mediating peripheral tolerance and preventing autoimmunity. Increased frequencies of CD4+CD25high T regulatory (T Reg) cells have been documented in the peripheral blood of patients with several types of cancer consistent with a role in tumour escape from immunological control. We have investigated the presence of TReg cells systemically and in situ in previously untreated patients with renal cell carcinoma (RCC). Results: We have shown that there is a significant increased frequency of CD4+CD25high T cells in RCC patients (n = 49) compared to normal donors (n = 38), respectively, 2.47% versus 1.50%; P < 0.0001. We confirmed these data using the FOXP3 marker of TReg cells in a subset of these patients and normal donors. The population of T Reg cells identified showed the expected phenotype with CD4 +CD25high population in both RCC patients and normal donors contained higher proportions of CD45RO and GITR than CD4 +CD25-/low populations and exhibiting suppressive activity in an anti-CD3 and anti-CD28 induced proliferation assay. CD4 +FOXP3+ T cells were detected in the tumour microenvironment by immunofluorescence and the numbers enumerated in lymphocytes recovered following enzymatic disaggregations of biopsies; their frequency was higher in the tumour than the peripheral blood of the same patients. The early follow up data show an association between higher peripheral blood regulatory T-cell count and adverse overall survival. Conclusion: These data confirm the increase of TReg cells in RCC patients and provide impetus to further investigate modulation of TReg activity in RCC patients as part of therapy.
AB - Background: Regulatory T cells are important in maintaining immune homeostasis, mediating peripheral tolerance and preventing autoimmunity. Increased frequencies of CD4+CD25high T regulatory (T Reg) cells have been documented in the peripheral blood of patients with several types of cancer consistent with a role in tumour escape from immunological control. We have investigated the presence of TReg cells systemically and in situ in previously untreated patients with renal cell carcinoma (RCC). Results: We have shown that there is a significant increased frequency of CD4+CD25high T cells in RCC patients (n = 49) compared to normal donors (n = 38), respectively, 2.47% versus 1.50%; P < 0.0001. We confirmed these data using the FOXP3 marker of TReg cells in a subset of these patients and normal donors. The population of T Reg cells identified showed the expected phenotype with CD4 +CD25high population in both RCC patients and normal donors contained higher proportions of CD45RO and GITR than CD4 +CD25-/low populations and exhibiting suppressive activity in an anti-CD3 and anti-CD28 induced proliferation assay. CD4 +FOXP3+ T cells were detected in the tumour microenvironment by immunofluorescence and the numbers enumerated in lymphocytes recovered following enzymatic disaggregations of biopsies; their frequency was higher in the tumour than the peripheral blood of the same patients. The early follow up data show an association between higher peripheral blood regulatory T-cell count and adverse overall survival. Conclusion: These data confirm the increase of TReg cells in RCC patients and provide impetus to further investigate modulation of TReg activity in RCC patients as part of therapy.
KW - Renal cell carcinoma
KW - Survival
KW - T regulatory cells
UR - http://www.scopus.com/inward/record.url?scp=34548162594&partnerID=8YFLogxK
U2 - 10.1007/s00262-007-0318-z
DO - 10.1007/s00262-007-0318-z
M3 - Article
C2 - 17487490
AN - SCOPUS:34548162594
SN - 0340-7004
VL - 56
SP - 1743
EP - 1753
JO - Cancer Immunology, Immunotherapy
JF - Cancer Immunology, Immunotherapy
IS - 11
ER -